Central Japan Railway Co. ADS (CJPRY) Financials Nov 14,
Central Japan Railway Co. ADS (CJPRY) Financials Nov 14, 2014, 8:10 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Central Japan Railway Co. ADS
Fiscal year is April-March. All values JPY millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 1.49T 1.5T 1.51T 1.59T 1.65T
Cost of Goods Sold (COGS) incl. D&A 1.04T 1.01T 991.8B 987.99B 920.01B
COGS excluding D&A 775.79B 751.72B 734.74B 747.79B 643.74B
Depreciation & Amortization Expense 268.22B 258.6B 257.06B 240.19B 276.27B
Depreciation - - - - -
Amortization of Intangibles - - - - -
Gross Income 442.62B 492.77B 516.52B 597.33B 732.54B
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 149.15B 143.42B 144B 171.19B 237.93B
Research & Development 25.43B 23.73B 25.85B 33.85B 93.53B
Other SG&A 123.72B 119.69B 118.15B 137.34B 144.4B
Other Operating Expense 0 0 0 0 0
Unusual Expense 702M 1.54B (192M) 464M 11.19B
EBIT after Unusual Expense (702M) (1.54B) 192M (464M) (11.19B)
Non Operating Income/Expense (15.02B) (87.45B) (10.02B) (10.35B) (838M)
Non-Operating Interest Income 213M 234M 186M 148M 152M
Equity in Affiliates (Pretax) 246M 311M 199M 2M 326M
Interest Expense 117.31B 36.26B 99.19B 89.29B 80.33B
Gross Interest Expense 117.31B 36.26B 99.19B 89.29B 80.33B
Interest Capitalized 0 0 0 0 0
Pretax Income 160.9B 224.65B 263.9B 326.19B 402.74B
Income Tax 66.64B 88.72B 127.79B 122.67B 142.67B
Income Tax - Current Domestic 74.26B 95.66B 108.2B 131.57B 143.58B
Income Tax - Current Foreign 0 0 0 0 -
Income Tax - Deferred Domestic (7.63B) (6.93B) 19.59B (8.91B) (906M)
Income Tax - Deferred Foreign 0 0 0 0 -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates - - - - -
Other After Tax Income (Expense) - 0 0 0 0
Consolidated Net Income 94.26B 135.92B 136.1B 203.52B 260.07B
Minority Interest Expense 2.5B 2.12B 3.32B 3.55B 4.38B
Net Income 91.76B 133.81B 132.78B 199.97B 255.69B
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 91.76B 133.81B 132.78B 199.97B 255.69B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 91.76B 133.81B 132.78B 199.97B 255.69B
EPS (Basic) 465.75 679.90 674.70 1,016.12 1,299.23
Basic Shares Outstanding 197.03M 196.8M 196.8M 196.8M 196.8M
EPS (Diluted) - 679.90 674.70 1,016.12 1,299.23
Diluted Shares Outstanding - 196.8M 196.8M 196.8M 196.8M
EBITDA 561.69B 607.95B 629.58B 666.34B 770.88B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
High Stakes and Deep Insights Await in Houston Cracking the nut of lower-middle market transactions ain’t a walk in the park. M&A Source®'s Fall 2026 Conference is gearing up to address the very dramas that lurk behind the scenes. Kicking off November 2-4 at the opulent JW Marriott in Houston, Texas, the event is looking to assemble a heavyweight lineup of...
Continue Reading
A Mess That Investors Can't Ignore If you're holding onto Endava plc shares, you've probably felt that gut-punch lately. Yeah, things are getting heated with a class action lawsuit alleging the company played fast and loose with its accounting practices. The complaint's about some shady dealings that may have thrown off investors' perceptions. The Core Allegations This...
Continue Reading
Big Moves in Immuno-Oncology: Astellas' Latest Bet You hear 'immuno-oncology,' you think breakthrough, right? Well, friends, that's what Astellas and Audax Biosciences are shooting for with their fresh handshake over DAX-044. On October 27, 2026, in Tokyo and Melbourne, the two outfits announced they're joining forces to bring this novel immunotherapy to the table. It's...
Continue Reading
A Major Step Forward in AI Infrastructure When two heavyweights clash, you better believe folks are paying attention. OneQode’s deal with AdaniConneX is like a shot across the bow in the AI infrastructure arena. They’re not just dipping a toe in India’s tech waters; they’re diving headfirst with 14 MW of data center muscle right there in Siruseri Sipcot, Chennai....
Continue Reading
A Deep Dive into Lynk Pharmaceuticals' Latest Revelation Lynk Pharmaceuticals just dropped a bombshell with their latest Phase III trial results for zemprocitinib. This selective JAK1 inhibitor seems to be bringing some serious game in the fight against moderate-to-severe rheumatoid arthritis (RA), especially for folks who haven't had much luck with biologics. The drug...
Continue Reading
A New Twist in Illinois: Cash Pop's Arrival Here's something fresh off the press: the Illinois Lottery is now on the ride with Brightstar's Cash Pop. This patented game isn't just another number pick—it's an engaging draw-based game featuring hourly draws with price tags of $1, $2, $5, and $10. It's like clockwork, and trust me, it's more than just the usual spin....
Continue Reading
Etisalat's Stellar Performance: A Deeper Dive When a company like Etisalat drops news of a whopping 46% increase in net profit year-over-year, you sit up and pay attention. Those numbers aren’t just a flash in the pan; they're the result of some serious strategic maneuvers and ripe market conditions. Etisalat isn't resting on its laurels, and their latest financials...
Continue Reading
Amgen's Steady Dividend: A Testament to Stability Diving into the mess that is today's biotech market, Amgen (NASDAQ:AMGN) stands out like a beacon of stability with its recent dividend announcement. The Board's decision to dole out a $2.52 per share dividend for the fourth quarter of 2026 showcases confidence amidst both promising ventures and looming uncertainties....
Continue Reading
A Meeting of Great Minds in Shanghai Alright, listen up. Shanghai's gearing up to be the nerve center for the 2026 World Laureates Forum (WLF), and it's seething with potential. This ain't your regular science fair; it's a lion's den of brainpower set to crack open the future of science and tech. With the heavy-hitters like Nobel and Turing laureates on the docket, you're...
Continue Reading
Dive into Mercado González's Cultural Opening Over in La Habra, Northgate González Market has just flung open the doors to its latest masterpiece: Mercado González. Picture this, a place where the mundanity of grocery shopping melds with a vibrant fiesta of Mexican cuisine, artisanry, and cultural vibes. They transformed an older store into something that commands not...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding Exelon's Upcoming Earnings Report Exelon Corporation (NASDAQ: EXC) is preparing to reveal its quarterly earnings in the near future. Investors are keenly awaiting the results, as they want insights into the company’s performance and projections for the following period. Analysts predict that Exelon will report an earnings per share (EPS) of $0.39,...
Continue Reading
Vallourec Invites Warrant Holders to General Meeting Vallourec has announced a significant upcoming event for its warrant holders, also known as BSA. This meeting is set to take place soon, providing an opportunity for holders to engage with the company's future decisions. Details of the Meeting The general meeting will occur at the Vallourec headquarters, where the...
Continue Reading
Pomerantz LLP Begins Investigation on Behalf of Molina Investors Pomerantz LLP has embarked on an investigation focusing on the interests of investors in Molina Healthcare, Inc. (NYSE: MOH). This inquiry aims to ascertain whether Molina and certain executives may have been involved in any unlawful activities related to securities fraud. Key Financial Findings and Investor...
Continue Reading
Unlocking E-commerce Potential in Grocery Retail In a transformative announcement, SymphonyAI, a leader in predictive and generative AI SaaS products for enterprises, has unveiled groundbreaking insights from its annual grocery e-commerce study. This research indicates a noteworthy 8% growth opportunity for retailers leveraging AI-driven strategies in their connected...
Continue Reading
Honda and Nissan's Strategic Talks Honda (NYSE:HMC) and Nissan (OTC:NSANY) have entered discussions that may lead to a potential merger, a significant move reflecting the shifting landscape of Japan's automotive industry. As these two giants explore deeper ties, it marks a notable strategy to face the competition posed by Tesla and various Chinese car manufacturers....
Continue Reading